Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2021 December;112(6) > Minerva Medica 2021 December;112(6):740-5

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  DIFFICULT CHALLENGES IN VASCULAR MEDICINE 

Minerva Medica 2021 December;112(6):740-5

DOI: 10.23736/S0026-4806.21.07474-7

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Treatment of retinal vein thrombosis: what about anticoagulants?

Omar M. RASLAN 1, 2, Alejandro LAZO-LANGNER 1, 3

1 Division of Hematology, Department of Medicine, Western University, London, ON, Canada; 2 Division of Hematology, Department of Medicine, College of Medicine, Jeddah University, Jeddah, Saudi Arabia; 3 Department of Epidemiology and Biostatistics Western University, London, ON, Canada



Retinal vein occlusion is an important cause of vision loss. The current treatment options are mainly directed to the prevention of neovascular complications and few studies have addressed to potential use of anticoagulant agents and other interventions targeting the coagulation system. Herein we review the general aspects of this condition focusing on the potential benefits of anticoagulant treatment.


KEY WORDS: Retinal vein occlusion; Anticoagulants; Therapeutics

inizio pagina